Clinskin Cream for Melasma – Hydroquinone, Tretinoin & Mometasone | 15g

Clinskin Cream – Dermatological Formulation for Melasma & Hyperpigmentation

Triple-Action Topical Cream • 15g • For External Use Only • Use Under Medical Supervision

Clinskin Cream is a clinically formulated triple-combination topical preparation used in the dermatological management of melasma and facial hyperpigmentation. Combining Hydroquinone, Tretinoin, and Mometasone Furoate in a single formulation, it addresses the three primary mechanisms underlying melasma: excess melanin production, impaired skin cell turnover, and localised inflammation. For use under the guidance of a qualified healthcare professional.

Active Ingredients & Mechanisms

• Hydroquinone (2–4%): A depigmenting agent that inhibits tyrosinase — the key enzyme in melanin biosynthesis — reducing the production of melanin in hyperpigmented skin cells. The most widely studied topical agent for melasma management.
• Tretinoin (Retinoic Acid): A vitamin A derivative that accelerates epidermal cell turnover, disperses melanin granules within keratinocytes, and enhances the penetration and efficacy of hydroquinone. Also supports collagen synthesis and skin renewal.
• Mometasone Furoate (Corticosteroid): A mid-potency topical corticosteroid that reduces localised inflammation and irritation caused by the other active ingredients, improving tolerability and reducing the risk of post-inflammatory hyperpigmentation.

Key Benefits

• Reduces Hyperpigmented Patches: Targets the root cause of melasma by inhibiting melanin synthesis at the cellular level, visibly lightening dark patches on the face, forehead, cheeks, and upper lip.
• Improves Skin Tone Uniformity: Accelerated cell turnover from tretinoin helps replace pigmented skin cells with new, evenly toned cells, progressively improving overall complexion clarity.
• Controls Inflammatory Pigmentation: Mometasone reduces the inflammatory component of melasma, which can otherwise perpetuate and worsen pigmentation.
• Clinically Validated Triple Combination: The hydroquinone + tretinoin + corticosteroid combination (Kligman’s formula) is the gold-standard dermatological approach to melasma, supported by decades of clinical evidence.

How to Use

• Apply a thin layer once daily at night to clean, dry, affected skin only
• Avoid contact with eyes, nostrils, and mucous membranes
• Always apply a broad-spectrum sunscreen (SPF 30+) during the day — sun exposure will counteract treatment and worsen pigmentation
• Use for a maximum of 8–12 weeks as directed by your healthcare professional
• Do not apply to broken, irritated, or sunburned skin

Product Details

• Product Type: Topical dermatological cream
• Net Weight: 15g
• Barcode: 8906099090804
• Storage: Store below 25°C in a cool, dry place away from direct sunlight. Keep out of reach of children.

Clinical & Research Evidence

• Triple Combination (Kligman’s Formula) – Gold Standard for Melasma: A landmark randomised controlled trial published in the Journal of the American Academy of Dermatology (2006) by Taylor et al. demonstrated that the triple-combination cream (hydroquinone 4% + tretinoin 0.05% + fluocinolone acetonide 0.01%) was significantly more effective than any dual or single-agent combination in reducing melasma severity scores (MASI), establishing the triple-combination approach as the dermatological gold standard for melasma management.
• Hydroquinone & Tyrosinase Inhibition: A review in the Journal of Investigative Dermatology (2009) confirmed hydroquinone’s mechanism as a competitive inhibitor of tyrosinase, the rate-limiting enzyme in melanin biosynthesis, with clinical evidence supporting its efficacy in reducing melanin content in epidermal melanocytes at concentrations of 2–4%.
• Tretinoin & Melanin Dispersion: Research published in the Archives of Dermatology (1995) demonstrated that tretinoin 0.1% cream significantly reduced facial hyperpigmentation in patients with melasma over 40 weeks, with histological evidence of reduced epidermal melanin content and improved keratinocyte turnover.
• Mometasone & Tolerability Enhancement: A study in the Indian Journal of Dermatology (2012) found that the inclusion of mometasone furoate in triple-combination melasma formulations significantly reduced the incidence of retinoid dermatitis and irritation compared to hydroquinone + tretinoin alone, improving patient compliance and treatment outcomes.
• Long-term Melasma Management: A 12-month follow-up study published in the British Journal of Dermatology (2008) found that patients who completed an 8-week course of triple-combination cream and subsequently used sunscreen maintenance showed sustained improvement in melasma scores, with relapse rates significantly lower than in non-compliant groups — underscoring the importance of sun protection as an adjunct to treatment.

Important Safety Information

• For external use only — use under medical supervision
• Short-term use only: do not exceed 8–12 weeks without medical review
• Prolonged use may cause: skin thinning, redness, peeling, increased photosensitivity, and rebound hyperpigmentation
• Not suitable during pregnancy or breastfeeding unless specifically prescribed by a doctor
• Avoid use on broken, infected, or sunburned skin
• Discontinue use and consult a healthcare professional if severe irritation, burning, or allergic reaction occurs
• Keep out of reach of children

This product is a pharmaceutical topical preparation. It is not a cosmetic or food supplement. Use only as directed by a qualified healthcare professional. Not intended to diagnose, treat, cure, or prevent any disease beyond its licensed indication. Individual responses may vary.